Navigation Links
ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
Date:11/6/2007

placebo. This treatment effect was not observed in the population of beta-1 Gly389 or the alpha-2c deletion carriers, indicating a pharmacogenetic interaction. As for AF prevention and CHF endpoints, patients with the favorable diplotype had treatment effects that were enhanced (reduction by 64% (p =0.001) in VT/VF occurrence by bucindolol as compared to placebo) over those for each individual favorable monotype.

About Bucindolol

Bucindolol is a next-generation beta-blocker and vasodilator for heart failure and other indications, which promises to be the first genetically-targeted cardiovascular drug. Extensive Phase 3 data show that bucindolol is likely to be an effective and well-tolerated therapy for many heart failure patients that can be targeted to those patients most likely to respond favorably, thereby overcoming a major problem with current treatment approaches. ARCA's founding scientists have confirmed genetic polymorphisms that interact with bucindolol's unique pharmacology to modify patient response.

A large substudy from a Phase 3 trial published in the July 25, 2006 edition of the Proceedings of the National Academy of Sciences shows that a common genetic variation in the beta-1 adrenergic receptor may help doctors identify heart failure patients who may benefit most from bucindolol. Data presented at the 2005 American Heart Association Meeting from the same DNA substudy demonstrates further enhancement of bucindolol's efficacy by targeting both the beta-1 variant and a variant of the alpha-2c-adrenergic receptor. A patient's response to bucindolol appears to be affected by genetic variations in two cardiovascular receptors.

ARCA is planning to submit a New Drug Application to the FDA for bucindolol in order to gain approval of the drug with a genetic test to assist physicians in determining whether bucindolol is an appropriate therapy for their heart failure patients. The Company has exclusive, worldwide rights to bucindolol.<
'/>"/>

SOURCE ARCA Discovery, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014 /PRNewswire/ ... operates in Southern California , today ... caregiving technology. Alta will be providing the innovative BeClose ... services. Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... to providing the kind of affordable 24/7 care our ...
(Date:11/21/2014)... 21, 2014   Rock Creek Pharmaceuticals, Inc., ... is scheduled to present at the Biotech Showcase™ 2015 ... on January 12-14, 2015. ... Rock Creek Pharmaceuticals, will present preclinical and clinical data ... exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the ...
(Date:11/21/2014)... Calif. , Nov. 21, 2014  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... of a stock purchase agreement to acquire 100% of ... Kingdom based distribution organization. The transaction closed ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
(Date:11/24/2014)... 24, 2014 Global electrophysiology devices ... by 2020, according to a new study by ... cardiac arrhythmias clubbed with growing global geriatric population ... Though still in the budding stage, the electrophysiology ... usage rates in the recent times, with physicians ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 A ... , London's pre-eminent pain-relief service and massage therapy ... Sports Massage (ESM). This newest sports massage ... The key difference between traditional sports massage and ... access the body's very own "reset button,” and ...
(Date:11/24/2014)... Alberta (PRWEB) November 24, 2014 ... people each day. They break up families, ruin ... is new hope for those that suffer,” says ... scientific research is showing that our specialized nutritional ... Hardy will appear on “Mind Over Matter”, the ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Dr. Michael ... Fertility Center, recently appeared on NBC to discuss egg freezing ... freezing has been trending in the news recently, with new ... procedure for women. , “[The companies] see it ... are on a career hot path.” Says Dr. Kettel. , ...
(Date:11/23/2014)... The report, “Market Snapshot: Aesthetic ... - Asia-Pacific” provides quantitative analysis of the three ... invasive body contouring devices, non-invasive body contouring devices ... size data by revenue and volume over the ... Japan, South Korea, Australia and India. It uses ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4
... screening, or don,t call back for the results, because they ... a disease. But many illnesses, such as HIV/AIDS and cancer, ... How can health care providers break down that resistance? ... new study by University of Florida psychologists Jennifer L. Howell ...
... WEDNESDAY, Dec. 21 (HealthDay News) -- Hospital patients who ... nearly twofold increased risk of developing delirium, but patients ... increased risk, researchers have found. Delirium is a ... hospital patients. The condition is usually temporary but can ...
... Tenn., Dec. 21, 2011 Armed with a new ability ... St. Jude Children,s Research Hospital have made a discovery they ... the retina. While much work remains, Oak Ridge National ... cells instead of just a few dozen. This tool has ...
... HealthDay Reporter , WEDNESDAY, Dec. 21 (HealthDay News) -- Ludwig ... composers of all time, yet he was deaf by the end ... issue of BMJ suggests that the progression of his ... University of Amsterdam in the Netherlands analyzed three styles of Beethoven,s ...
... News) -- Life expectancy is a topic many disabled seniors ... have that discussion, a new study finds. It included ... had multiple illnesses and disabilities and lived in a community-based, ... had been diagnosed with a specific terminal illness. Interviews ...
... Neuroimaging Technology, researchers use functional MRI brain scans to ... activity. They then employ computerized machine learning (ML) methods ... or sometimes the thought process of human ... decoding." In a new ...
Cached Medicine News:Health News:Self-affirmation may break down resistance to medical screening 2Health News:Move to Hospital Isolation Unit Linked to Raised Delirium Risk 2Health News:ORNL image analysis prowess advances retina research 2Health News:Did Beethoven's Hearing Loss Shape His Compositions? 2Health News:Most Sick or Disabled Seniors Want Docs to Say How Long They Have 2Health News:UCLA neuroscientists demonstrate crucial advances in 'brain reading' 2Health News:UCLA neuroscientists demonstrate crucial advances in 'brain reading' 3Health News:UCLA neuroscientists demonstrate crucial advances in 'brain reading' 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: